Editor’s mask: Rep the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Heart.
Pfizer asked the FDA on Thursday to enlarge emergency employ authorization of its COVID-19 vaccine to young folks ages 5 to 11.
The The question comes after the drugmaker submitted medical trial files to the FDA on Sept. 28. Pfizer said the survey of two,268 young folks confirmed the vaccine modified into win and produced a tough immune response.
Contributors within the research obtained a decrease dose of the vaccine, 10 micrograms. Their response 2 weeks after a 2d dose modified into reportedly equal to the immune protection in a retain watch over community of 16- to 25-year-olds who obtained the entirely authorized 30-microgram doses.
Currently, the Pfizer EUA applies to 12- to 15-year-olds and folks eligible for a Pfizer booster shot. The drugmaker obtained fats FDA acclaim for the vaccine for Americans 16 years and older in August.
The submitting for authorization in 5- to 11-year-olds comes as total circumstances of COVID -19 within the US continue to state no. The decrease suggestions a descend in recent circumstances in young folks for the fourth consecutive week, in step with diagnosis of files from the American Academy of Pediatrics and the Kid’s Health Center Association.
The next stream is an FDA decision on whether to enlarge the unique emergency employ authorization (EUA) for young folks to the youthful age community.
Timing of any legitimate notice from the agency is unknown . However almost definitely in anticipation of on the present time’s submitting, the FDA already scheduled a meeting of its Vaccines and Linked Natural Merchandise Advisory Committee for Oct. 25.
Twitter: @pfizer, Oct. 7, 2021.
Damian McNamara is a workers journalist basically based in Miami. He covers a mountainous sequence of medical specialties, at the side of infectious diseases, gastroenterology and neurology. Be aware Damian on Twitter: @MedReporter.